216 results on '"Marra, F. ."'
Search Results
2. BOC.02.7: UNDERDILATED NEOADJUVANT-TIPS IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION CANDIDATES TO OPERATIVE INTERVENTIONS
3. BOC.02.4: EPISODIC OVERT HEPATIC ENCEPHALOPATHY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT DOES NOT INCREASE MORTALITY IN PATIENTS WITH CIRRHOSIS
4. OC.05.2: FIRST AND FURTHER LIVER DECOMPENSATION IN PATIENTS WITH METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE: WHAT CLINICAL IMPACT?
5. Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis
6. Clinical impact of relative dose intensity of cabozantinib during the first 8 weeks and of subsequent dose reductions in patients with unresectable hepatocellular carcinoma
7. Altered fatty acid metabolism rewires cholangiocarcinoma stemness features
8. Predictors of extrahepatic progression in patients with hepatocellular carcinoma receiving transarterial chemoembolization
9. Inhibition of the Extracellular Signal-Regulated Kinase ERK5 induces an increased expression of the Epidermal Growth Factor receptor and sensitizes hepatocarcinoma cells to gefitinib
10. MerTK-expressing macrophages promote the malignant features of cholangiocarcinoma cells
11. Longer transplant-free and liver-related event-free survival in obeticholic acid-treated patients with primary biliary cholangitis compared to external controls from two large real-world cohorts
12. Role of the interplay between ERK5 and hypoxia in intrahepatic cholangiocarcinoma cells
13. Contribution of GD2 ganglioside to aggressivness of human cholangiocarcinoma
14. Hepatocyte depletion of ERK5 impairs the response to lipotoxic oxidative stress resulting in defective insulin receptor signaling
15. Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced nonalcoholic fatty liver disease
16. Incidence and risk factors of esophagogastric varices bleeding in cirrhotic patients with advanced hepatocellular carcinoma treated with lenvatinib
17. Fatty Acid Synthase expression promotes the malignant features of cholangiocarcinoma cells and predicts shorter survival in patients
18. Long-term results from the Italian real-world experience on obeticholic acid treatment in primary biliary cholangitis: The RECAPITULATE study
19. Liver function is a predictor of survival in patients with hepatocellular carcinoma in best supportive care
20. Predictors of Serious Adverse Event and Non-response in Cirrhotic Patients With Primary Biliary Cholangitis under Obeticholic Acid
21. Modulation of the cholangiocarcinoma stem-like compartment by monounsaturated fatty acids
22. Comparison of therapeutic outcomes of liver resection and transarterial chemoembolization in multifocal HCC: a propensity score-matched analysis
23. Cross-talk between MerTK-expressing stromal cells and cholangiocarcinoma
24. Predictors of survival of patients with hepatocellular carcinoma in best supportive care
25. Macrophage MerTK promotes a profibrogenic cross-talk with hepatic stellate cells via soluble mediators
26. Transjugular intra-hepatic portosystemic shunt (TIPS) in elderly patients: preliminary analysis of a multicenter retrospective cohort.
27. Role of ganglioside GD2 in the stem-like compartment of intrahepatic cholangiocarcinoma
28. The synergic effect of metformin with atezolizumab/ bevacizumab in masld hcc patients: a retrospective study from arte multicentric Italian dataset
29. Involvement of the potassium channel ERG1 in cholangiocarcinoma
30. Can AtezoBev be a safe and effective option for treating hepatocellular carcinoma in patients with Child-Pugh B cirrhosis? A retrospective multicenter real-world study
31. Placement of a trans-jugular intrahepatic portosystemic shunt (TIPS) modifies the expression of soluble mediators by circulating monocytes
32. Underdilated neoadjuvant-TIPS in patients with cirrhosis and portal hypertension candidates to operative interventions
33. External Validation of the ExPeCT TIPS Prediction Model in a North American Cohort
34. First and further liver decompensation in patients with metabolic-dysfunction associated steatotic liver disease: what clinical impact?
35. Oxidative stress-induced fibrinogen modifications in liver transplant recipients: unraveling a novel potential mechanism for cardiovascular risk
36. Biochemical response to obeticholic acid drives liver stiffness variation over time and the risk of liver-related events in patients with primary biliary cholangitis
37. Underdilation strategy for TIPS placement reduces incidence of overt hepatic encephalopathy without affecting clinical efficacy and survival: results of a multicenter prospective Italian study
38. End-procedural complete haemodynamic response may not be essential for the clinical success of TIPS in patients with cirrhosis
39. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease: A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee
40. Pattern of macrovascular invasion in patients with hepatocellular carcinoma influences treatment and outcome
41. Abnormal glycosphingolipid patterns in human cholangiocarcinoma stem-like subsets
42. Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma
43. Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma: efficacy, safety and prognostic factors
44. The protease-inhibitor serpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma
45. Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells
46. Fatty Acids regulate the biology of cholangiocarcinoma cells
47. Myeloid cell-specific deficiency of ERK5 regulates the response to liver regeneration after partial hepatectomy (PH) in mice
48. Mitochondrial oxidative metabolism contributes to maintain a cancer stem cell phenotype in cholangiocarcinoma
49. Hepatocyte-specific deletion of ERK5 worsens insulin resistance in a murine model of nonalcoholic fatty liver disease (NAFLD)
50. Regulation of the biology of cholangiocarcinoma (CCA) cells by Extracellular-signal-regulated kinase 5 (ERK5)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.